AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Larimar Therapeutics Inc (LRMR) has a strong liquidity position with $175.4 million in cash and marketable securities, extending its cash runway into Q4 2026. The company operates in the biotechnology sector, focusing on rare diseases using innovative technology. Despite a challenging market environment, Larimar maintains a stable financial outlook with a low debt-to-equity ratio.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet